Effect of valsartan on kidney outcomes in people with impaired glucose tolerance.

Article Details

Citation
Copy to clipboard

Currie G, Bethel MA, Holzhauer B, Haffner SM, Holman RR, McMurray JJV

Effect of valsartan on kidney outcomes in people with impaired glucose tolerance.

Diabetes Obes Metab. 2017 Jun;19(6):791-799. doi: 10.1111/dom.12877. Epub 2017 Mar 17.

PubMed ID
28093841 [ View in PubMed
]
Abstract

AIMS: To examine the effect of valsartan on kidney outcomes in patients with impaired glucose tolerance (IGT). METHODS: In a double-blind randomized trial, 9306 patients with IGT were assigned to valsartan (160 mg daily) or placebo. The co-primary endpoints were the development of diabetes and two composite cardiovascular outcomes. Prespecified renal endpoints included: the composite of renal death, end-stage renal disease (ESRD) or doubling of serum creatinine; estimated glomerular filtration rate (eGFR)

DrugBank Data that Cites this Article

Drugs